ZYME Zymeworks Inc. - Common Stock
$27.70
价格 · 八月 19, 2026
截至...的财报数据 八月 6, 2026
52周区间
$14–$30
87% of range
分析师评级
BUY
18 analysts
目标价
$40
+46% upside
P/E (TTM)
-25.6
ROE
-26.9%
净利润率
-76.6%
关于 Zymeworks Inc. - Common Stock 公司概况（来自维基百科）
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
阅读更多
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics.
In September 2019, Zymeworks announced that, following their clinical trials, it has been confirmed that their ZW25 monotherapy can provide durable disease control in patients with a variety of HER2-expressing solid tumors that have progressed following standard of care treatments.
In May 2022, Zymeworks rejected an unsolicited takeover proposal from a Dubai hedge fund, All Blue Falcons FZE, an arm of All Blue Capital.
Azymetric
This is an IgG1-based heterodimeric antibody scaffold that consists of two different heavy chains engineered to exclusively assemble into a single molecule, allowing bi-specific binding to two different antigens or drug targets. The Azymetric scaffold is engineered by making amino acid changes in the CH3 region of the constant Fc domain of the IgG1. This scaffold can also be engineered with tailored effector function and optimized serum half-life.
Awards and recognition
Deal of the Year, Lifesciences BC Awards, 2018
Life Sciences Company of the Year, Lifesciences BC Awards, 2016
Emerging company of the year – Health, BIOTECanada Gold Leaf Awards, 2015
12th Place, BC's Leading Innovators, 2011
Life Science Emerging Rocket, 2009, 2010, 2011
Early stage Company of the year – Industrial & Agriculture, BIOTECanada Gold Leaf Awards, 2009
== References ==
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
ZYME 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$27.70
市值
$2.07B
P/E (TTM)
-25.6
每股收益 (TTM)
$-1.08
营收 (TTM)
$106M
股息收益率
—
ROE
-26.9%
负债/权益
—
52周区间
$14 – $30
ZYME 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
$106M
2020-12-31
→
2025-12-31
EPS
$-1.08
2020-12-31
→
2025-12-31
自由现金流
$-35M
2023-12-31
→
2025-12-31
利润率
-76.6%
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
ZYME
同行中位数
P/E (TTM)
-25.6
—
P/S (TTM) (市销率 (TTM))
19.5
418.4
P/B (市净率)
7.7
2.3
Price / FCF (股价/自由现金流)
-59.9
—
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
ZYME
同行中位数
Operating Margin (营业利润率)
-87.3%
—
Net Profit Margin (净利润率)
-76.6%
-549.8%
ROA
-20.0%
-41.8%
ROE
-26.9%
-54.1%
ROIC
-35.1%
—
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
ZYME
同行中位数
Current Ratio (流动比率)
5.9
12.6
Quick Ratio (速动比率)
1.1
—
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
ZYME
同行中位数
Revenue YoY (营收同比增长)
38.9%
—
Revenue CAGR 3Y (营收3年复合年增长率)
-36.4%
—
Revenue CAGR 5Y (营收5年复合年增长率)
22.2%
—
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
ZYME
同行中位数
ZYME 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
买入
18 位分析师
- 强烈买入 6 33.3%
- 买入 11 61.1%
- 持有 1 5.6%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
12 位分析师 · 2026-08-16
中位数
$38.50
← 低于所有目标
$27.70
最低
$31.00
最高
$58.00
中位数目标
$38.50
+39.0%
平均目标
$40.33
+45.6%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
0.01%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $-0.62 | $-0.50 | -0.12% |
| 2026年3月31日 | $-0.59 | $-0.20 | -0.39% |
| 2025年12月31日 | $-0.55 | $-0.42 | -0.13% |
| 2025年9月30日 | $-0.26 | $-0.33 | 0.07% |
| 2025年6月30日 | $0.03 | $-0.50 | 0.53% |
| 2025年3月31日 | $-0.30 | $-0.42 | 0.12% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| ZYME | $1.97B | -24.4 | 38.9% | -76.6% | -26.9% | — |
| AUPH | $2.11B | 7.7 | 20.4% | 101.5% | 62.7% | — |
| ABUS | $926M | -28.3 | 128.2% | -237.9% | -42.0% | — |
| ACOG | $141M | -5.5 | — | -202.2% | -43.8% | — |
| PMN | $15M | -0.3 | — | — | 4840.3% | — |
| XENE | $3.59B | -10.3 | — | -4612.1% | -56.9% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 14
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $106M | $76M | $76M | $412M | $27M | |
| R&D Expense | · | · | $144M | $209M | $200M | |
| SG&A Expense | $62M | $62M | $70M | $73M | $43M | |
| Operating Expenses | $199M | $213M | $214M | $282M | $242M | |
| Operating Income | $-93M | $-137M | $-138M | $131M | $-216M | |
| Other Non-op | $51.0K | $-218.0K | $291.0K | $-42.0K | $118.0K | |
| Pretax Income | $-80M | $-117M | $-119M | $135M | $-212M | |
| Income Tax | $1M | $6M | $-568.0K | $11M | $-516.0K | |
| Net Income | $-81M | $-123M | $-119M | $124M | $-212M | |
| EPS (Basic) | $-1.08 | $-1.62 | $-1.72 | $1.91 | $-4.11 | |
| EPS (Diluted) | $-1.08 | $-1.62 | $-1.72 | $1.90 | $-4.61 | |
| Shares (Basic) | 75,404,897 | 75,846,681 | 68,863,010 | 65,194,775 | 51,553,869 | |
| Shares (Diluted) | 75,413,396 | 75,878,738 | 68,863,010 | 65,249,184 | 52,131,596 | |
| EBITDA | $-93M | $-137M | $-138M | · | · |
资产负债表 23
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $41M | $66M | $158M | $401M | $202M | |
| Short-term Investments | · | · | $217M | $91M | $51M | |
| Receivables | $5M | $56M | $19M | $33M | $16M | |
| Prepaid Expense | $15M | $19M | $19M | $19M | $20M | |
| Current Assets | $249M | $300M | $413M | $545M | $288M | |
| PP&E (Net) | $16M | $18M | $20M | $25M | $23M | |
| PP&E (Gross) | $36M | $35M | $41M | $38M | $37M | |
| Accum. Depreciation | $21M | $18M | $21M | $13M | $14M | |
| Goodwill | $12M | $12M | $12M | $12M | $12M | |
| Intangibles | $1M | $5M | $8M | $9M | $4M | |
| Total Assets | $347M | $463M | $581M | $649M | $389M | |
| Accounts Payable | $36M | $60M | $46M | $87M | $63M | |
| Current Liabilities | $42M | $88M | $56M | $96M | $72M | |
| Capital Leases | $15M | $16M | $22M | $25M | $31M | |
| Deferred Tax | $6M | $5M | $3M | $2M | $2M | |
| Other Non-current Liabilities | $278.0K | $923.0K | $2M | $3M | $3M | |
| Total Liabilities | $78M | $124M | $116M | $156M | $140M | |
| Common Stock | $1.11B | $1.02B | $997M | $886M | $741M | |
| Retained Earnings | $-953M | $-830M | $-677M | $-559M | $-683M | |
| AOCI | $-6M | $-7M | $-7M | $-7M | $-7M | |
| Stockholders' Equity | $269M | $339M | $465M | $493M | $249M | |
| Liabilities + Equity | $347M | $463M | $581M | $649M | $389M | |
| Shares Outstanding | 74,638,413 | 68,964,319 | 70,115,997 | 63,059,501 | 46,633,935 |
现金流 14
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Stock-based Comp | $28M | $18M | $8M | $4M | $11M | |
| Deferred Tax | $945.0K | $691.0K | $-757.0K | $2M | $-953.0K | |
| Amort. of Intangibles | $4M | $4M | $3M | $1M | $3M | |
| Restructuring | · | · | $0 | · | · | |
| Operating Cash Flow | $-33M | $-110M | $-118M | $144M | $-192M | |
| CapEx | $2M | $2M | $2M | $8M | $12M | |
| Investing Cash Flow | $27M | $39M | $-207M | $-54M | $145M | |
| Stock Issued | $0 | $0 | $26M | $108M | $0 | |
| Stock Repurchased | $42M | $30M | $0 | $0 | · | |
| Net Stock Activity | $-42M | $-30M | $26M | · | · | |
| Financing Cash Flow | $-19M | $-20M | $82M | $109M | $8M | |
| Net Change in Cash | $-25M | $-91M | $-243M | $199M | $-40M | |
| Taxes Paid | $1M | $3M | $165.0K | $10M | · | |
| Free Cash Flow | $-35M | $-112M | $-121M | · | · |
盈利能力 7
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Operating Margin | -87.3% | -179.7% | -181.6% | · | · | |
| Net Margin | -76.6% | -160.8% | -156.1% | · | · | |
| Pretax Margin | -75.3% | -152.8% | -156.9% | · | · | |
| EBITDA Margin | -87.3% | -179.7% | -181.6% | · | · | |
| ROA | -20.0% | -23.5% | -19.3% | · | · | |
| ROE | -26.9% | -34.8% | -26.7% | · | · | |
| ROIC | -35.1% | -42.6% | -29.6% | · | · |
流动性与偿付能力 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 5.9 | 3.4 | 7.4 | · | · | |
| Quick Ratio | 1.1 | 1.4 | 7.1 | · | · |
效率 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.1 | 0.1 | · | · | |
| Receivables Turnover | 3.5 | 2.0 | 2.9 | · | · |
增长率 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue YoY | 38.9% | 0.38% | -81.6% | 1446.0% | -31.5% | |
| Revenue CAGR 3Y | -36.4% | 41.9% | 25.0% | · | · | |
| Revenue CAGR 5Y | 22.2% | · | · | · | · |
估值 (TTM) 10
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue TTM | $106M | $76M | $76M | $412M | · | |
| Net Income TTM | $-81M | $-123M | $-119M | $124M | · | |
| Market Cap | $1.97B | $1.01B | $729M | · | · | |
| P/E | -24.4 | -9.0 | -6.0 | 4.1 | · | |
| P/S | 18.5 | 13.2 | 9.6 | · | · | |
| P/B | 7.3 | 3.0 | 1.6 | · | · | |
| P / Tangible Book | 7.7 | 3.1 | 1.6 | 1.0 | · | |
| P / Cash Flow | -59.5 | -9.2 | -6.2 | · | · | |
| P / FCF | -56.9 | -9.0 | -6.0 | · | · | |
| Earnings Yield | -4.1% | -11.1% | -16.6% | 24.2% | · |
损益表 14
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $2M | $3M | $28M | $49M | $27M | $31M | $16M | $19M | $10M | $17M | $17M | $7M | $36M | $402M | $3M | |
| R&D Expense | · | · | · | · | · | · | · | · | · | $32M | · | $33M | $39M | $46M | · | $37M | |
| SG&A Expense | $19M | $15M | $15M | $14M | $15M | $17M | $16M | $14M | $16M | $16M | $15M | $17M | $22M | $17M | $30M | $16M | |
| Operating Expenses | $47M | $50M | $47M | $50M | $49M | $53M | $53M | $50M | $62M | $48M | $40M | $50M | $61M | $63M | $83M | $53M | |
| Operating Income | $-42M | $-47M | $-44M | $-22M | $-674.0K | $-26M | $-22M | $-34M | $-43M | $-38M | $-23M | $-33M | $-54M | $-27M | $319M | $-50M | |
| Other Non-op | $196.0K | $120.0K | $-18.0K | $26.0K | $-621.0K | $49.0K | $-253.0K | $-37.0K | $53.0K | $19.0K | $-278.0K | $370.0K | $230.0K | $-31.0K | $-27.0K | $-98.0K | |
| Pretax Income | $-45M | $-46M | $-41M | $-18M | $2M | $-22M | $-18M | $-30M | $-38M | $-32M | $-19M | $-28M | $-49M | $-23M | $320M | $-48M | |
| Income Tax | $-273.0K | $-2M | $-270.0K | $1M | $-186.0K | $496.0K | $6M | $226.0K | $68.0K | $75.0K | $-5M | $1M | $2M | $1M | $11M | $-29.0K | |
| Net Income | $-45M | $-44M | $-41M | $-20M | $2M | $-23M | $-24M | $-30M | $-38M | $-32M | $-14M | $-29M | $-51M | $-24M | $309M | $-48M | |
| EPS (Basic) | $-0.62 | $-0.59 | $-0.55 | $-0.26 | $0.03 | $-0.30 | $-0.32 | $-0.39 | $-0.49 | $-0.42 | $-0.19 | $-0.41 | $-0.76 | $-0.36 | $4.78 | $-0.72 | |
| EPS (Diluted) | $-0.62 | $-0.59 | $-0.55 | $-0.26 | $0.03 | $-0.30 | $-0.32 | $-0.39 | $-0.49 | $-0.42 | $-0.18 | $-0.41 | $-0.76 | $-0.37 | $4.78 | $-0.72 | |
| Shares (Basic) | 72,993,313 | 74,668,790 | -150,871,069 | 75,767,778 | 75,337,168 | 75,171,020 | -152,889,276 | 76,128,531 | 76,392,593 | 76,214,833 | -135,733,099 | 70,575,773 | 67,281,028 | 66,739,308 | -129,002,888 | 66,477,016 | |
| Shares (Diluted) | 72,993,313 | 74,694,762 | -152,966,654 | 75,775,214 | 77,378,449 | 75,226,387 | -152,922,738 | 76,157,101 | 76,396,217 | 76,248,158 | -135,739,304 | 70,575,773 | 67,284,511 | 66,742,030 | -128,961,927 | 66,478,157 | |
| EBITDA | $-42M | $-47M | · | $-22M | $-674.0K | $-26M | · | $-34M | $-43M | $-38M | · | $-33M | $-54M | $-27M | · | $-50M |
资产负债表 23
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $179M | $244M | $41M | $65M | $98M | $76M | $66M | $122M | $71M | $115M | · | $94M | $142M | $182M | · | $96M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | $201M | $198M | $159M | · | $70M | |
| Receivables | $6M | $5M | $5M | $29M | $3M | $25M | $56M | $24M | $32M | $31M | · | $67M | $49M | $67M | · | $7M | |
| Prepaid Expense | $22M | $16M | $15M | $10M | $12M | $17M | $19M | $23M | $21M | $18M | · | $12M | $31M | $19M | · | $18M | |
| Current Assets | $298M | $386M | $249M | $292M | $296M | $306M | $300M | $344M | $383M | $394M | · | $375M | $420M | $426M | · | $191M | |
| PP&E (Net) | $14M | $15M | $16M | $16M | $16M | $17M | $18M | $18M | $18M | $19M | · | $21M | $22M | $24M | · | $26M | |
| PP&E (Gross) | · | · | $36M | · | · | · | $35M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $21M | · | · | · | $18M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | · | $12M | $12M | $12M | · | $12M | |
| Intangibles | $998.0K | $1M | $1M | $1M | $2M | $3M | $5M | $6M | $7M | $7M | · | $8M | $7M | $8M | · | $9M | |
| Total Assets | $397M | $478M | $347M | $397M | $408M | $426M | $463M | $487M | $516M | $554M | · | $556M | $602M | $601M | · | $300M | |
| Accounts Payable | $27M | $30M | $36M | $34M | $31M | $38M | $60M | $52M | $44M | $47M | · | $68M | $70M | $59M | · | $52M | |
| Current Liabilities | $47M | $36M | $42M | $42M | $39M | $65M | $88M | $84M | $55M | $57M | · | $73M | $94M | $67M | · | $58M | |
| Capital Leases | $13M | $14M | $15M | $16M | $15M | $15M | $16M | $17M | $17M | $21M | · | $22M | $23M | $24M | · | $25M | |
| Deferred Tax | $4M | $4M | $6M | $5M | $5M | $5M | $5M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Other Non-current Liabilities | $278.0K | $278.0K | $278.0K | $278.0K | $828.0K | $856.0K | $923.0K | $929.0K | $1M | $2M | · | $2M | $4M | $4M | · | $3M | |
| Total Liabilities | $317M | $315M | $78M | $77M | $74M | $101M | $124M | $120M | $109M | $116M | · | $132M | $153M | $127M | · | $121M | |
| Common Stock | $1.13B | $1.13B | $1.11B | $1.09B | $1.07B | $1.02B | $1.02B | $1.01B | $1.01B | $1.00B | · | $932M | $929M | $900M | · | $885M | |
| Retained Earnings | $-1.17B | $-1.07B | $-953M | $-886M | $-851M | $-853M | $-830M | $-798M | $-747M | $-709M | · | $-663M | $-634M | $-583M | · | $-868M | |
| AOCI | $-7M | $-7M | $-6M | $-6M | $-6M | $-6M | $-7M | $-6M | $-8M | $-8M | · | $-8M | $-8M | $-6M | · | $-7M | |
| Stockholders' Equity | $80M | $164M | $269M | $320M | $335M | $325M | $339M | $367M | $406M | $438M | $465M | $424M | $449M | $474M | $493M | $180M | |
| Liabilities + Equity | $397M | $478M | $347M | $397M | $408M | $426M | $463M | $487M | $516M | $554M | · | $556M | $602M | $601M | · | $300M | |
| Shares Outstanding | 71,412,072 | 73,102,689 | 74,638,413 | 75,139,281 | 74,846,147 | 69,584,811 | 68,964,319 | 69,584,882 | 70,831,545 | 70,677,106 | · | 67,922,559 | 67,687,384 | 64,083,770 | · | 61,694,387 |
现金流 12
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $11M | $7M | $9M | $7M | $6M | $6M | $5M | $5M | $5M | $4M | $3M | $2M | $367.0K | $2M | $4M | $5M | |
| Amort. of Intangibles | $176.0K | $176.0K | $185.0K | $648.0K | $2M | $2M | $2M | $980.0K | $812.0K | $702.0K | $673.0K | $672.0K | $678.0K | $679.0K | $529.0K | $166.0K | |
| Operating Cash Flow | $-32M | $-46M | $-10M | $-31M | $12M | $-3M | $-42M | $-6M | $-25M | $-38M | $14M | $-43M | $-6M | $-83M | $327M | $-73M | |
| CapEx | $0 | $216.0K | $581.0K | $410.0K | $514.0K | $16.0K | $314.0K | $899.0K | $593.0K | $185.0K | $356.0K | $930.0K | $802.0K | $386.0K | $348.0K | $981.0K | |
| Investing Cash Flow | $17M | $70M | $5M | $368.0K | $9M | $12M | $-6M | $72M | $-20M | $-7M | $-1M | $-7M | $-61M | $-138M | $-22M | $-30M | |
| Stock Issued | · | · | · | · | · | · | $0 | $0 | · | · | $0 | $0 | $26M | $0 | $0 | $0 | |
| Stock Repurchased | $52M | $76M | $25M | $16M | $0 | $0 | $9M | · | · | · | $0 | · | · | · | · | · | |
| Net Stock Activity | · | $-76M | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $-50M | $179M | $-19M | $-2M | $1M | $1M | $-9M | $-15M | $1M | $2M | $51M | $2M | $28M | $2M | $-377.0K | $628.0K | |
| Net Change in Cash | $-65M | $203M | $-24M | $-33M | $22M | $10M | $-56M | $51M | $-44M | $-43M | $63M | $-48M | $-39M | $-219M | $305M | $-103M | |
| Taxes Paid | $863.0K | $245.0K | $107.0K | $660.0K | $196.0K | $387.0K | $3M | $106.0K | $106.0K | $0 | · | · | · | · | · | · | |
| Free Cash Flow | · | $-46M | · | · | · | $-3M | · | · | · | $-38M | · | · | · | $-84M | · | · |
盈利能力 7
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -919.0% | -1956.7% | · | -80.1% | -1.4% | -94.5% | · | -213.8% | -222.9% | -376.9% | · | -201.4% | -772.8% | -76.7% | · | -1914.0% | |
| Net Margin | -980.8% | -1834.0% | · | -71.0% | 4.8% | -83.5% | · | -186.6% | -195.8% | -315.6% | · | -173.8% | -730.5% | -68.5% | · | -1818.6% | |
| Pretax Margin | -986.8% | -1925.0% | · | -66.1% | 4.4% | -81.7% | · | -185.2% | -195.5% | -314.8% | · | -167.1% | -706.9% | -64.5% | · | -1819.7% | |
| EBITDA Margin | -919.0% | -1956.7% | · | -80.1% | -1.4% | -94.5% | · | -213.8% | -222.9% | -376.9% | · | -201.4% | -772.8% | -76.7% | · | -1914.0% | |
| ROA | -11.2% | -9.8% | · | -4.4% | 0.50% | -4.6% | · | -5.7% | -6.7% | -5.5% | · | -6.7% | -17.0% | -8.1% | · | -31.9% | |
| ROE | -21.7% | -18.1% | · | -5.7% | 0.63% | -5.9% | · | -7.5% | -8.8% | -6.9% | · | -9.5% | -22.8% | -10.3% | · | -53.2% | |
| ROIC | -52.2% | -27.4% | · | -7.4% | -0.22% | -8.1% | · | -9.4% | -10.6% | -8.6% | · | -8.2% | -12.5% | -6.1% | · | -28.0% |
流动性与偿付能力 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.3 | 10.8 | · | 6.9 | 7.7 | 4.7 | · | 4.1 | 7.0 | 6.9 | · | 5.1 | 4.5 | 6.3 | · | 3.3 | |
| Quick Ratio | 3.9 | 7.0 | · | 2.2 | 2.6 | 1.5 | · | 1.7 | 1.9 | 2.6 | · | 5.0 | 4.2 | 6.1 | · | 3.0 |
效率 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.1 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.1 | · | 0.0 | |
| Receivables Turnover | 1.1 | 0.2 | · | 1.0 | 2.8 | 1.0 | · | 0.4 | 0.5 | 0.2 | · | 0.4 | 0.3 | 1.1 | · | 0.8 |
估值 (TTM) 10
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $83M | $106M | · | $119M | $111M | $72M | · | $62M | $53M | $69M | · | $62M | $51M | $46M | · | $14M | |
| Net Income TTM | $-106M | $-84M | · | $-70M | $-88M | $-122M | · | $-128M | $-149M | $-136M | · | $-152M | $-188M | $-209M | · | $-246M | |
| Market Cap | $1.87B | $1.83B | · | $1.28B | $939M | $829M | · | $873M | $603M | $744M | · | $431M | $585M | $579M | · | $379M | |
| P/E | -18.2 | -22.4 | · | -18.6 | -10.9 | -7.4 | · | -7.3 | -4.1 | -5.4 | · | -2.8 | -3.1 | -2.8 | · | -1.5 | |
| P/S | 22.4 | 17.3 | · | 10.7 | 8.5 | 11.4 | · | 14.1 | 11.4 | 10.8 | · | 7.0 | 11.5 | 12.7 | · | 26.4 | |
| P/B | 23.2 | 11.2 | · | 4.0 | 2.8 | 2.6 | · | 2.4 | 1.5 | 1.7 | · | 1.0 | 1.3 | 1.2 | · | 2.1 | |
| P / Tangible Book | 27.7 | 12.2 | · | 4.2 | 2.9 | 2.7 | · | 2.5 | 1.6 | 1.8 | · | 1.1 | 1.4 | 1.3 | · | 2.4 | |
| P / Cash Flow | · | -40.0 | · | · | · | -243.3 | · | · | · | -19.7 | · | · | · | -7.0 | · | · | |
| P / FCF | · | -39.9 | · | · | · | -242.1 | · | · | · | -19.6 | · | · | · | -6.9 | · | · | |
| Earnings Yield | -5.5% | -4.5% | · | -5.4% | -9.2% | -13.4% | · | -13.6% | -24.4% | -18.6% | · | -35.6% | -32.6% | -35.9% | · | -67.2% |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $106M | $76M | $76M | $412M | $27M |
| 营业利润率 % | -87.3% | -179.7% | -181.6% | — | — |
| 净收入 | $-81M | $-123M | $-119M | $124M | $-212M |
| 稀释后每股收益 (EPS) | $-1.08 | $-1.62 | $-1.72 | $1.90 | $-4.61 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流动比率 | 5.9 | 3.4 | 7.4 | — | — |
| 速动比率 | 1.1 | 1.4 | 7.1 | — | — |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | $-35M | $-112M | $-121M | — | — |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 218 家申报者 · $1.5B 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 30 (-11 与上一季度对比) | 30 (-1 与上一季度对比) | 56 (-17 与上一季度对比) | 68 (+9 与上一季度对比) | +200K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
公司内部人士 28 位内幕人士 · 12 位高管 · 17 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Kenneth Galbraith | Chair & CEO | 2026年1月12日 A | 226842 | 0 | 4 | $-3337929 |
| Kristin Stafford | EVP, Chief Financial Officer | 2026年4月6日 A | — | 0 | 0 | $0 |
| Christopher Astle | SVP & Chief Financial Officer | 2024年1月5日 A | 6503 | 0 | 0 | $0 |
| Neil A Klompas | President & COO | 2023年3月10日 M | 17032 | 0 | 0 | $0 |
| Mark Hollywood | EVP & Chief Operating Officer | 2026年7月6日 A | 133852 | 0 | 1 | $-138740 |
| Paul R Schneider | EVP, General Counsel | 2026年5月13日 A | — | 0 | 0 | $0 |
| Adam Schayowitz | EVP, Head of Research & Development | 2026年4月9日 A | — | 0 | 0 | $0 |
| Scott Platshon | EVP, Chief Business Officer | 2026年4月9日 A | — | 0 | 0 | $0 |
| Paul Andrew Moore | Chief Scientific Officer | 2026年1月12日 A | 48497 | 0 | 3 | $-721486 |
| Jeffrey T L Smith | EVP & Chief Medical Officer | 2026年1月12日 M | 26708 | 0 | 2 | $-475562 |
| Leone D Patterson | EVP, Chief Bus & Fin Officer | 2026年1月6日 A | 459 | 0 | 0 | $0 |
| Neil Josephson | Chief Medical Officer | 2022年11月10日 M | 14449 | 0 | 0 | $0 |
| Gregory A. Ciongoli | 董事 | 2026年1月12日 A | 488500 | 0 | 0 | $0 |
| Alessandra Cesano | 董事 | 2026年1月12日 A | — | 0 | 0 | $0 |
| Carlos Campoy | 董事 | 2026年1月12日 A | — | 0 | 0 | $0 |
| Robert E Landry | 董事 | 2026年1月12日 A | — | 0 | 0 | $0 |
| Kelvin Neu | 董事 | 2026年1月12日 A | — | 0 | 0 | $0 |
| Susan Mahony | 董事 | 2026年1月12日 A | — | 0 | 0 | $0 |
| Brian N Cherry | 董事 | 2026年1月12日 A | — | 0 | 0 | $0 |
| EcoR1 Capital, LLC | 董事 | 2025年1月17日 P | 15720161 | 0 | 0 | $0 |
| Nancy Davidson | 董事 | 2024年12月10日 A | — | 0 | 0 | $0 |
| Neil Gallagher | 董事 | 2024年12月10日 A | — | 0 | 0 | $0 |
| Derek John Michael Miller | 董事 | 2024年12月10日 A | — | 0 | 0 | $0 |
| Troy Cox | 董事 | 2024年12月10日 A | — | 0 | 0 | $0 |
| Kenneth J. Hillan | 董事 | 2023年12月7日 A | — | 0 | 0 | $0 |
| Hollings Renton | 董事 | 2023年12月7日 A | — | 0 | 0 | $0 |
| Natalie Sacks | 董事 | 2022年12月21日 A | — | 0 | 0 | $0 |
| Lota S. Zoth | 董事 | 2022年12月21日 A | — | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 2 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC, Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P. ×8 申报 | 2025年11月19日 | 30.70% | 修订 | 董事会活动 | SEC |
| All Blue Falcons FZE, Daniel Edward Llewellen Cookson ×2 申报 | 2022年12月28日 | — | 初始申报 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 42 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| CANC · Tema ETF Trust | 1.51% | 105615 NS | 2026年5月31日 | N-PORT |
| BBC · ETFis Series Trust I | 0.80% | 10832 NS | 2026年4月30日 | N-PORT |
| FYC · First Trust Exchange-Traded Alpha... | 0.49% | 186247 NS | 2026年4月30日 | N-PORT |
| FYX · First Trust Exchange-Traded Alpha... | 0.25% | 110902 NS | 2026年4月30日 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0.15% | 16669 NS | 2026年5月31日 | N-PORT |
| FAD · First Trust Exchange-Traded Alpha... | 0.10% | 17393 NS | 2026年4月30日 | N-PORT |
| BIB · ProShares Trust | 0.09% | 2766 NS | 2026年5月31日 | N-PORT |
| PSC · Principal Exchange-Traded Funds | 0.09% | 80480 NS | 2026年6月30日 | N-PORT |
| RSSL · Global X Funds | 0.04% | 21639 NS | 2026年4月30日 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.04% | 189866 NS | 2026年4月30日 | N-PORT |
| ITWO · ProShares Trust | 0.03% | 2345 NS | 2026年5月31日 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.03% | 10887 NS | 2026年5月31日 | N-PORT |
| UWM · ProShares Trust | 0.02% | 1834 NS | 2026年5月31日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.02% | 16794 NS | 2026年4月30日 | N-PORT |
| URTY · ProShares Trust | 0.01% | 1855 NS | 2026年5月31日 | N-PORT |
| TILT · FlexShares Trust | 0.01% | 5236 NS | 2026年4月30日 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.01% | 1925 NS | 2026年5月31日 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0.01% | 26839 NS | 2026年5月31日 | N-PORT |
| HDG · ProShares Trust | 0.01% | 47 NS | 2026年5月31日 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 5213 NS | 2026年4月30日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 72902 NS | 2026年4月30日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 12951 NS | 2026年4月30日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 8364 NS | 2026年4月30日 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.00% | 130 NS | 2026年4月30日 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 每日 |
| VFMO · VANGUARD WELLINGTON FUND | — | — | 2026年7月30日 | 每日 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 2026年7月15日 | 每日 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 2026年7月15日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 2026年7月15日 | 每日 |
| IWV · iShares Trust | — | — | 2026年8月18日 | 每日 |
| IWO · iShares Trust | — | — | 2026年8月18日 | 每日 |
| IWM · iShares Trust | — | — | 2026年8月18日 | 每日 |
| IBB · iShares Trust | — | — | 2026年8月18日 | 每日 |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | 2026年7月23日 | 每日 |
| OMFS · Invesco Exchange-Traded Self-Inde... | — | — | 2026年7月13日 | 每日 |
| VHT · VANGUARD WORLD FUND | — | — | 2026年7月20日 | 每日 |
| ISCB · iShares Trust | — | — | 2026年8月4日 | 每日 |
| ISCG · iShares Trust | — | — | 2026年8月4日 | 每日 |
| ISCV · iShares Trust | — | — | 2026年8月4日 | 每日 |
| SMMV · iShares Trust | — | — | 2026年8月18日 | 每日 |
| WSML · iShares Trust | — | — | 2026年8月4日 | 每日 |
| IBBQ · Invesco Exchange-Traded Fund Trus... | — | — | 2026年7月20日 | 每日 |